Monthly Archives: March 2017

Monday 6th March 2017

Sorry, this entry is only available in French. Lequotidiendumedecin.fr rend compte des travaux de l’équipe de recherche Inserm 1068, publiés dans Cell Reports, qui a identifié qu’une molécule d’ARN particulier, un microARN, joue le rôle d’interrupteur moléculaire capable de réguler la prolifération des cellules souches cancéreuses (CSC) dans les cancers du sein. « La piste des […]

Posted in Synthèse de presse | Comments closed

Inserm in the world Top 10 most innovative public bodies, up one place compared to last year.

L’Inserm se classe 9e dans le « Top 25 Global Innovators – Government » Reuters/Clarivate, qui évalue la capacité d’innovation des organisations publiques en fonction de l’impact de leur production scientifique et de leurs brevets.

Posted in Press releases, Institutional and special event | Tagged | Comments closed

Friday 3rd March 2017

Sorry, this entry is only available in French. Le CNRS a appelé hier la société Biosantech, qui développe un projet de vaccin contre le VIH, à « ne pas éveiller d’espoirs qui se révèleraient infondés », et a souligné qu’il n’avait plus de relations avec les recherches de cette entreprise, rapporte l’AFP. Dans un communiqué commun, le […]

Posted in Synthèse de presse | Comments closed

Thursday 2nd March 2017

Sorry, this entry is only available in French. L’AFP, Lemonde.fr et Libération rapportent que des chercheurs ont traité avec succès grâce à une thérapie génique un jeune garçon atteint d’une forme sévère d’anémie chronique héréditaire, la drépanocytose. Il s’agit du « premier patient au monde à avoir bénéficié de ce traitement novateur », précise l’agence de presse. […]

Posted in Synthèse de presse | Comments closed

Breast cancer: identification of a molecular switch that controls cancer stem cells

Some cancer cells are resistant to treatment and persist. If they are capable of proliferating again, even a very small number of these cells may be enough to reconstitute a tumour after or despite treatment. Various approaches to eliminate these “cancer stem cells” (CSCs) have been tried in recent years: targeted therapies, vaccination and tumour starvation. In an article published in the journal Cell Reports, Christophe Ginestier, Inserm Research Fellow at the Cancer Research Center of Marseille (CRCM, Aix-Marseille University/CNRS/Institut Paoli-Calmettes), and his collaborators identify a specific RNA[1] molecule that plays the role of a molecular switch that can “turn off” or “turn on” CSC proliferation in breast cancers.

Posted in Cell biology, development and evolution, Cancer, Press releases, Genetics, genomics and bioinformatics | Tagged | Comments closed

Wednesday 1st March 2017

Sorry, this entry is only available in French. La plupart des quotidiens annoncent qu’un premier plan de lutte contre les violences faites aux enfants sera dévoilé ce jour par Laurence Rossignol, ministre des Familles, de l’Enfance et des Droits des femmes, qui est conçu sur 3 ans (2017-2019) et qui fixe quatre objectifs : quantifier, comprendre, […]

Posted in Synthèse de presse | Comments closed

1 March 2017: A plan for action on violence against children

Wednesday 1 March 2017 will see the unveiling of the interministerial plan for “mobilisation and action on violence against children” by Laurence Rossignol, Minister for Families, Children and Women’s Rights.

Posted in In the media, France | Comments closed

Sickle cell disease : remission of disease symptoms in the world’s first patient treated using gene therapy

A team led by Prof. Marina Cavazzana, working at Necker Hospital for Sick Children, AP-HP, and the Imagine Institute (AP-HP/Inserm/Paris Descartes University) performed gene therapy on a 13-year-old patient with severe sickle cell anaemia in October 2014 as part of a phase I/II clinical trial. Conducted in collaboration with Prof. Philippe Leboulch (CEA/Faculties of Medicine at Paris-Sud and Harvard Universities), who developed the vector used, and supervised the preclinical studies, this innovative treatment provided complete remission from the clinical signs of the disease, and the correction of biological signs. Results (15-month follow up after transplantation) are published in the New England Journal of Medicine on 2 March 2017, and confirm the efficacy of this new therapy of the future.

Posted in Press releases, Genetics, genomics and bioinformatics, Public health | Tagged | Comments closed
fermer
fermer
RSS Youtube